|
1
|
Bahadoram S, Davoodi M, Hassanzadeh S,
Bahadoram M, Barahman M and Mafakher L: Renal cell carcinoma: An
overview of the epidemiology, diagnosis, and treatment. G Ital
Nefrol. 39:2022–vol3. 2022.PubMed/NCBI
|
|
2
|
Bex A, Albiges L, Ljungberg B, Bensalah K,
Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, et al:
Updated European association of urology guidelines for
cytoreductive nephrectomy in patients with synchronous metastatic
clear-cell renal cell carcinoma. Eur Urol. 74:805–809. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Botrugno OA, Fayard E, Annicotte JS, Haby
C, Brennan T, Wendling O, Tanaka T, Kodama T, Thomas W, Auwerx J
and Schoonjans K: Synergy between LRH-1 and beta-catenin induces G1
cyclin-mediated cell proliferation. Mol Cell. 15:499–509. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gobbo S, Eble JN, Grignon DJ, Martignoni
G, MacLennan GT, Shah RB, Zhang S, Brunelli M and Cheng L: Clear
cell papillary renal cell carcinoma: A distinct histopathologic and
molecular genetic entity. Am J Surg Pathol. 32:1239–1245. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gao X, Liu Y, Hong S, Yang H, Guan B and
Ma X: PLEKHA4 is associated with tumour microenvironment, stemness,
proliferation and poor prognosis of gliomas. J Integr Neurosci.
22:1352023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shami Shah A, Batrouni AG, Kim D, Punyala
A, Cao W, Han C, Goldberg ML, Smolka MB and Baskin JM:
PLEKHA4/kramer attenuates dishevelled ubiquitination to modulate
Wnt and planar cell polarity signaling. Cell Rep. 27:2157–2170.e8.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tanton H, Sewastianik T, Seo HS, Remillard
D, Pierre RS, Bala P, Aitymbayev D, Dennis P, Adler K, Geffken E,
et al: A novel β-catenin/BCL9 complex inhibitor blocks oncogenic
Wnt signaling and disrupts cholesterol homeostasis in colorectal
cancer. Sci Adv. 8:eabm31082022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nusse R and Clevers H: Wnt/β-catenin
signaling, disease, and emerging therapeutic modalities. Cell.
169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Q, Krause M, Samoylenko A and Vainio S:
Wnt signaling in renal cell carcinoma. Cancers (Basel). 8:572016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu X, Zhang M, Xu F and Jiang S: Wnt
signaling in breast cancer: Biological mechanisms, challenges and
opportunities. Mol Cancer. 19:1652020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Y, Xiao X, Chen H, Chen Z, Hu K and Yin
D: Transcription factor NFYA promotes G1/S cell cycle transition
and cell proliferation by transactivating cyclin D1 and CDK4 in
clear cell renal cell carcinoma. Am J Cancer Res. 10:2446–2463.
2020.PubMed/NCBI
|
|
14
|
Ji J, Xu Y, Xie M, He X, Ren D, Qiu T, Liu
W, Chen Z, Shi W, Zhang Z, et al: VHL-HIF-2α axis-induced SEMA6A
upregulation stabilized β-catenin to drive clear cell renal cell
carcinoma progression. Cell Death Dis. 14:832023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jones J, Out H, Spentzos D, Kolia S, Inan
M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, et al: Gene
signatures of progression and metastasis in renal cell cancer. Clin
Cancer Res. 11:5730–5739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wozniak MB, Le Calvez-Kelm F,
Abedi-Ardekani B, Byrnes G, Durand G, Carreira C, Michelon J,
Janout V, Holcatova I, Foretova L, et al: Integrative genome-wide
gene expression profiling of clear cell renal cell carcinoma in
Czech Republic and in the United States. PLoS One. 8:e578862013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maretzky T, Reiss K, Ludwig A, Buchholz J,
Scholz F, Proksch E, de Strooper B, Hartmann D and Saftig P: ADAM10
mediates E-cadherin shedding and regulates epithelial cell-cell
adhesion, migration, and beta-catenin translocation. Proc Natl Acad
Sci USA. 102:9182–9187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shami Shah A, Cao X, White AC and Baskin
JM: PLEKHA4 promotes Wnt/β-catenin signaling-mediated
G1-S transition and proliferation in melanoma. Cancer
Res. 81:2029–2043. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hedberg Y, Davoodi E, Roos G, Ljungberg B
and Landberg G: Cyclin-D1 expression in human renal-cell carcinoma.
Int J Cancer. 84:268–272. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Albrecht LV, Tejeda-Muñoz N and De
Robertis EM: Cell Biology of canonical Wnt signaling. Annu Rev Cell
Dev Biol. 37:369–389. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Niehrs C: The complex world of WNT
receptor signalling. Nat Rev Mol Cell Biol. 13:767–779. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bian J, Dannappel M, Wan C and Firestein
R: Transcriptional regulation of Wnt/β-catenin pathway in
colorectal cancer. Cells. 9:21252020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hashemi M, Hasani S, Hajimazdarany S,
Ghadyani F, Olyaee Y, Khodadadi M, Ziyarani MF, Dehghanpour A,
Salehi H, Kakavand A, et al: Biological functions and molecular
interactions of Wnt/β-catenin in breast cancer: Revisiting
signaling networks. Int J Biol Macromol. 232:1233772023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y and Wang X: Targeting the
Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol.
13:1652020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Krishnamurthy N and Kurzrock R: Targeting
the Wnt/beta-catenin pathway in cancer: Update on effectors and
inhibitors. Cancer Treat Rev. 62:50–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Neiheisel A, Kaur M, Ma N, Havard P and
Shenoy AK: Wnt pathway modulators in cancer therapeutics: An update
on completed and ongoing clinical trials. Int J Cancer.
150:727–740. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang N, Wei P, Gong A, Chiu WT, Lee HT,
Colman H, Huang H, Xue J, Liu M, Wang Y, et al: FoxM1 promotes
β-catenin nuclear localization and controls Wnt target-gene
expression and glioma tumorigenesis. Cancer Cell. 20:427–442. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li P, Chen T, Kuang P, Liu F, Li Z, Liu F,
Wang Y, Zhang W and Cai X: Aurora-A/FOXO3A/SKP2 axis promotes tumor
progression in clear cell renal cell carcinoma and dual-targeting
Aurora-A/SKP2 shows synthetic lethality. Cell Death Dis.
13:6062022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Swiatek M, Jancewicz I, Kluebsoongnoen J,
Zub R, Maassen A, Kubala S, Udomkit A, Siedlecki JA, Sarnowski TJ
and Sarnowska E: Various forms of HIF-1α protein characterize the
clear cell renal cell carcinoma cell lines. IUBMB Life.
72:1220–1232. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He W, Cong Z, Niu C, Cheng F, Yi T, Yao Z,
Zhang Y, Jiang X, Sun X, Niu Z and Fu Q: A prognostic signature
based on genes associated with m6A/m5C/m1A/m7G modifications and
its immunological characteristics in clear cell renal cell
carcinoma. Sci Rep. 14:187082024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yin X, Wang J and Zhang J: Identification
of biomarkers of chromophobe renal cell carcinoma by weighted gene
co-expression network analysis. Cancer Cell Int. 18:2062018.
View Article : Google Scholar : PubMed/NCBI
|
